Tirzepatide Associated With Improved Health‐Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT ‐4
Authors' conclusion
In participants with overweight or obesity, continued tirzepatide treatment was associated with maintaining HRQoL improvement, while treatment withdrawal resulted in worsening of HRQoL.
Study context
- Population
- Adults with obesity or overweight who achieved tirzepatide maximum tolerated dose (MTD) during a 36-week lead-in
- Participants
- 670 adults
- Comparison
- Continued tirzepatide MTD vs switch to placebo
- Primary endpoint
- Health-related quality of life (HRQoL) by PROs (SF-36v2, IWQOL-Lite-CT, EQ-5D-5L)
- Follow-up
- W36 to W88
Methodological detailsrandomized (1:1), 36-week lead-in, post hoc analysis
- Randomized (1:1)
- 36-week lead-in
- Post hoc analysis
Primary result
As reported in the abstract
HRQoL (PROs)
- PRO improvements from W0 to W36 with tirzepatide were maintained from W36 to W88 with continued tirzepatide vs placebo
Further findings
PROs by weight reduction and baseline physical function (tirzepatide-treated)
- Greater weight reduction and baseline physical function limitations: numerically greater PRO improvements
- Post hoc analysis
PROs by weight regain (placebo)
- Greater weight regain after switch to placebo associated with worsening of PROs
- Post hoc analysis
Original publication
Tirzepatide Associated With Improved Health‐Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT ‐4. Obesity (Silver Spring). Published 3 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →